Most Recent
Drug companies drop bid for ACCC approval of Revlimid patent settlement
Competition & Consumer Protection 2022-07-29 11:44 am By Cat Fredenburgh

Bristol-Myers Squibb unit Celgene and two generic drug makers have withdrawn an application for ACCC approval of a patent settlement that would have allowed for an early launch of a generic version of blockbuster cancer drug Revlimid.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

ACCC says agreement to settle Revlimid patent suit could violate cartel laws
Intellectual Property 2022-03-23 2:53 pm By Cat Fredenburgh

The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

After GetSwift, judge could not hear split trial in Revlimid patent case, court told
Intellectual Property 2021-07-20 8:39 pm By Christine Caulfield

A proposal by Bristol-Myers Squibb-owned Celgene to split a second trial into two more hearings in a dispute over patents covering the pharmaceutical maker’s top selling cancer drug Revlimid would result in wasted costs, wasted time and require a second judge, a court has been told.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Juno and Bristol-Myers Squibb suffer losses in Revlimid patent war
Intellectual Property 2021-03-25 1:58 pm By Miklos Bolza

A patent battle between Juno Pharmaceuticals and Bristol-Myers Squibb over the blockbuster drug Revlimid has seen both sides suffer early losses, with a judge dismissing strike out and summary dismissal applications by the drug makers.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.